Our management team has interdisciplinary skills spanning biology, chemistry, bioinformatics, image processing, high content screening, large scale cloud software infrastructure and big data analytics.
Yochi Slonim, Ms.C., co-founder & CEO
Yochi Slonim is a serial entrepreneur with a track record of over 30 years in software and biotech. He co-founded Anima in 2005 and as CEO has been driving its drug discovery platform and pipeline.
Prior to Anima, Yochi has built several companies from their early stage, through all stages of product development, marketing and sales and eventually turned them into successful large exits.
He was a co-founder of Mercury Interactive. As CTO and VP R&D from the company's early days he created product vision and strategy and led a multi-product organization of 200 developers. After going public and reaching revenues of over $1B annually, Mercury was acquired by HP for $4.5B.
As Senior VP of products and marketing for Tecnomatix, a public NASDAQ company, he led a 500 people organization of 4 divisions that generated revenues of $100m until the company was acquired by UGS for $230m.
In 2000, Yochi was founder and CEO of Identify. The company reached revenues of $50m in in less than 5 years and was acquired by BMC in 2006 for $150m in cash.
Yochi founded ffwd.me (www.ffwd.me), a unique startup acceleration program where he led a team that worked with over 25 startups in diverse areas and technologies, developing strategy, products and go to market operations while raising multiple rounds of financing from VCs and private investors.
As one of Israel's leading speakers on the subject of startup positioning and company building, several of Yochi's approachable and amusing lectures can be found on Youtube ("Youtube Yochi Slonim")
Dr. Smilansky is the inventor of our PSM technology and is in charge for its future technology directions through internal development and a large network of scientific collaborations. As a renowned expert in image processing, Dr. Smilansky also leads the development of Anima's PSM image analysis algorithms.
A mathematician by training, he started his career in Scitex and Orbotech, developing high throughput image processing algorithms. As a former VP R&D at Compugen and Procognia, Zeev has over 20 years of industry experience in biology, spanning the areas of genomics, proteomics and bio-informatics.
Iris Alroy, PhD., Vice President, R&D
Dr. Iris Alroy has broad background and more than 15 experience in small molecule drug discovery, preclinical development and development of IND-enabling studies. Dr. Alroy was VP Discovery at Proteologics, where she established several research programs for the identification of small molecules inhibiting the activity of E3 ubiquitin ligases in HIV-1 and Cancer. Subsequently she was VP R&D at Pharmos Corp., in which she managed organic and medicinal chemistry, biology and pharmacology groups. Under her guidance efficacy animal models were setup, validated and used for testing lead molecules in pain and inflammation up to Phase I study in inflammatory pain.
Dr. Alroy was entrepreneur and CEO of startup biotech companies, Fusimab, Ltd., ProMining Therapeutics Ltd., developing bispecific antibodies and small molecules, respectively. Dr. Alroy successfully managed drug discovery and development projects (e.g. staffing, patent protections, budget), collaborated with researchers in academia and large pharmaceutical companies, and produced peer-reviewed publications.
Yossi Oulu, Ms.C., Vice President, Digital Technologies
Mr. Oulu is a software executive with over 20 years of experience in building and managing complex software and infrastructure products. he held various senior management positions at Mercury Interactive where he was responsible for the development of the LoadRunner product line that reached over $1B in sales and dominated the category of software Load testing.
At Anima, Mr. Oulu is responsible for the development of our digital strategy around a cloud based software infrastructure for automation and management of our high content screening platform.
David Sheppard, PhD., Head of Chemistry
Dr. Sheppard runs Anima's chemistry group from Cambridge, UK. He has over 15 years of experience in small molecule drug discovery. Prior to joining Anima, Dr. Sheppard was a Director at BioFocus, now part of the Charles River group, where he led, managed and motivated a group of computational and synthetic chemists along with leading drug discovery programs for external clients. The experience gained in working for a top global contract research organisation (CRO) gave Dr. Sheppard a broad expertise in numerous therapeutic areas and emerging targets including those associated with the proteasome, epigenetic modulation and a diversity of compound classes including peptides, peptidomimetic, macrocyclic, fragment, reversible covalent and traditional small molecule inhibitors.
Before joining BioFocus, Dr Sheppard worked for Medivir as a senior computational chemist and before that at Amgen. Dr. Sheppard obtained his degree in chemistry from the University of St Andrews, Scotland and he obtained his PhD from the University of Manchester in 2000. Throughout his career, Dr Sheppard has set up and managed numerous successful collaborations with academic groups, he has authored numerous high quality peer reviewed publications and is a scientific reviewer for the Wellcome Trust.
Avi Eliassaf, Chief Operating Officer
Mr. Eliassaf oversees Anima's day-to-day operational, legal and budget processes. He has over 25 years of experience in senior executive management positions. From 2013-2016 he was CFO of SalesPredict, responsible for finance and legal, fund raising, data regulation and administration of the Israeli parent company and its USA subsidiary. SalesPredict was acquired by eBay in 2016. From 2001-2006 he was VP R&D and General Manager at Identify Software, leading a multinational development and support team of 80 people until the company's acquisition by BMC for $150m. From 1984-2001 , Mr. Eliassaf has held various executive positions with Tecnomatix, through the company's IPO and growth phases to annual revenues of over $100m. As VP R&D and General Manager he managed a 200 employees development, services and support operation until the acquisition by UGS for $238m. Prior to that he spent 7 years in the US, where he managed the technical operation of the company’s US subsidiary, planning and executing complex projects with big enterprise customers.